Bio-Rad Laboratories-B
BIO.B
365.08
0.00
0.00%
Bio-Rad Laboratories-B
US · BIO.B
#1492 by market cap
Listed 1970
365.08
0.00
0.00%
Live - 5344 symbols - heartbeat 71s ago
· 2026-10-07 19:54
After-hours
365.08
0.00%
- Market cap
- 9.76B
- P/E (TTM)i
- 44.47
- P/Bi
- 1.36
- EPSi
- 27.85
- Div yieldi
- 0.00%
- 52W posi
- 100%
Reader sentiment
Are you bullish or bearish on BIO.B?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.54, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +0.65% YoY
Margins
- Gross margin
- 51.87%
- Operating margin
- 8.46%
- Net margin
- 29.42%
Key ratios & quality
- Enterprise valuei
- 9.46B
- Altman Z-Scorei
- 3.54
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.29B | 2.31B | 2.55B | 2.92B | 2.80B | 2.67B | 2.57B | 2.58B |
| Gross profit | 1.22B | 1.26B | 1.44B | 1.64B | 1.57B | 1.43B | 1.38B | 1.34B |
| Selling & admin expenses | 834.78M | 824.63M | 798.80M | 877.12M | 827.80M | 841.70M | 814.00M | 844.30M |
| Research & development | 199.20M | 202.71M | 217.76M | 260.64M | 256.90M | 247.40M | 295.90M | 275.60M |
| Operating profit | 189.17M | 229.66M | 421.33M | 500.34M | 475.10M | 337.80M | 269.00M | 218.60M |
| Pretax profit | 512.66M | 2.26B | 4.92B | 5.45B | -4.70B | -850.10M | -2.34B | 995.50M |
| Tax | 147.05M | 502.41M | 1.10B | 1.19B | -1.08B | -212.80M | -498.30M | 235.60M |
| Net profit | 365.61M | 1.76B | 3.81B | 4.25B | -3.63B | -637.30M | -1.84B | 759.90M |
| Basic EPS | 12 | 59 | 128 | 143 | -122 | -22 | -65 | 28 |
| Diluted EPS | 12.10 | 58.27 | 126.47 | 140.83 | -121.79 | -21.82 | -65.36 | 27.85 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 585.40M | 651.60M | 653.00M | 693.20M | 592.10M | 651.00M |
| Gross profit | 306.00M | 345.30M | 343.40M | 345.20M | 309.40M | 345.80M |
| Selling & admin expenses | 208.80M | 207.70M | 206.80M | 221.00M | 212.40M | 212.00M |
| Research & development | 73.50M | 60.50M | 71.30M | 70.30M | 62.90M | 61.20M |
| Operating profit | 23.70M | 77.10M | 63.90M | 53.90M | 34.10M | 72.60M |
| Pretax profit | 83.40M | 414.00M | -431.10M | 929.20M | -689.80M | 542.10M |
| Tax | 19.40M | 96.20M | -89.20M | 209.20M | -162.70M | 170.70M |
| Net profit | 64.00M | 317.80M | -341.90M | 720.00M | -527.10M | 371.40M |
| Basic EPS | 2 | 12 | -13 | 27 | -20 | 14 |
| Diluted EPS | 2.29 | 11.67 | -12.70 | 26.65 | -19.55 | 13.85 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 2.02B | 2.18B | 2.14B | 1.99B | 3.16B | 3.05B | 3.03B | 2.91B |
| Cash & ST investments | 844.80M | 1.11B | 991.12M | 869.92M | 1.79B | 1.61B | 1.66B | 1.54B |
| Inventory | 583.82M | 554.01M | 622.25M | 572.24M | 719.32M | 780.50M | 760.00M | 740.70M |
| Total assets | 5.61B | 8.01B | 12.97B | 17.80B | 13.50B | 12.30B | 9.36B | 10.58B |
| Total current liabilities | 450.80M | 905.50M | 631.54M | 680.94M | 568.71M | 522.80M | 467.80M | 517.00M |
| Short-term debt | 493.00K | 461.57M | 38.31M | 36.92M | 36.80M | 40.90M | 42.90M | 37.40M |
| Long-term debt | 438.94M | 2.40M | 1.30M | 10.51M | 1.20B | 1.20B | 1.20B | 1.20B |
| Total liabilities | 1,590,737,000.00 | 2,253,802,000.00 | 3,092,678,000.00 | 4,114,157,000.00 | 3,886,414,000.00 | 3,557,900,000.00 | 2,794,800,000.00 | 3,122,900,000.00 |
| Total equity | 4.02B | 5.76B | 9.88B | 13.69B | 9.62B | 8.74B | 6.57B | 7.45B |
| Retained earnings | 3.72B | 5.47B | 9.27B | 13.53B | 9.90B | 9.26B | 7.42B | 8.18B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.04B | 2.81B | 2.84B | 2.91B | 2.94B | 3.02B |
| Cash & ST investments | 1.66B | 1.37B | 1.42B | 1.54B | 1.56B | 1.62B |
| Inventory | 790.10M | 798.80M | 783.20M | 740.70M | 770.50M | 780.60M |
| Total assets | 9.53B | 10.21B | 9.70B | 10.58B | 9.79B | 10.25B |
| Total current liabilities | 506.60M | 548.90M | 522.30M | 517.00M | 917.00M | 961.30M |
| Short-term debt | 42.50M | 40.60M | 38.10M | 37.40M | 436.70M | 434.30M |
| Long-term debt | 1.20B | 1.20B | 1.20B | 1.20B | 802.90M | 803.00M |
| Total liabilities | 2,847,500,000.00 | 3,085,400,000.00 | 2,959,600,000.00 | 3,122,900,000.00 | 2,938,700,000.00 | 3,078,100,000.00 |
| Total equity | 6.68B | 7.13B | 6.74B | 7.45B | 6.85B | 7.17B |
| Retained earnings | 7.48B | 7.80B | 7.46B | 8.18B | 7.65B | 8.02B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 285.49M | 457.90M | 584.97M | 669.46M | 194.40M | 374.90M | 455.20M | 532.20M |
| Depreciation & amortization | 138.10M | 134.20M | 138.60M | 137.60M | 137.30M | 145.90M | 151.60M | 165.40M |
| Free cash flow | 155.67M | 359.37M | 476.41M | 535.72M | 80.10M | 218.20M | 266.20M | 374.60M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -48.91M | -28.00M | -100.00M | -50.00M | -215.70M | -428.70M | -203.60M | -295.50M |
| Ending cash balance | 434.16M | 662.65M | 667.12M | 471.13M | 434.50M | 404.40M | 489.80M | 532.20M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 129.90M | 116.50M | 120.90M | 164.90M | 108.10M | 98.70M |
| Depreciation & amortization | 38.10M | 40.60M | 44.20M | 42.50M | 40.90M | 41.10M |
| Free cash flow | 95.50M | 70.80M | 89.20M | 119.10M | 78.10M | 66.70M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -101.90M | -140.20M | -53.40M | 0 | -47.80M | -31.50M |
| Ending cash balance | 523.10M | 371.70M | 398.20M | 532.20M | 509.00M | 518.80M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 10.52 | 35.98 | 48.69 | 36.06 | -31.16 | -6.94 | -24.09 | 10.84 |
| ROA %i | 7.40 | 25.83 | 36.28 | 27.62 | -23.20 | -4.94 | -17.03 | 7.62 |
| ROIC %i | 9.30 | 32.27 | 46.14 | 35.28 | -29.27 | -6.39 | -20.68 | 8.63 |
| 5-year avg ROE %i | 4.94 | 11.33 | 20.15 | 27.17 | 20.05 | 16.56 | 4.55 | -3.05 |
| EBIT margin %i | 23.44 | 98.83 | 193.65 | 186.13 | -166.51 | -29.97 | -89.37 | 40.43 |
| FCF / sales %i | 6.80 | 15.55 | 18.71 | 18.33 | 2.87 | 8.17 | 10.37 | 14.50 |
| Current ratioi | 4.49 | 2.41 | 3.39 | 2.92 | 5.55 | 5.83 | 6.48 | 5.62 |
| Quick ratioi | 2.74 | 1.66 | 2.23 | 1.90 | 4.02 | 4.01 | 4.53 | 3.87 |
| Debt / assetsi | 7.83 | 8.13 | 1.74 | 1.26 | 10.28 | 11.43 | 14.68 | 13.11 |
| LT debt / equityi | 10.92 | 3.29 | 1.90 | 1.36 | 14.05 | 15.61 | 20.27 | 18.09 |
| Interest coveragei | 22.39 | 97.56 | 225.49 | 3,507.22 | -122.43 | -16.20 | -46.90 | 21.32 |
| Revenue CAGR (3Y) %i | 4.27 | 3.78 | 5.63 | 8.48 | 6.62 | 1.62 | -4.24 | -2.68 |
| Net income CAGR (3Y) %i | 49.58 | 307.45 | 214.81 | 126.60 | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | 28.81 | 68.97 | -- | 50.98 | -39.37 | -22.92 | -20.79 | 67.23 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -27.51 | 4.59 | -9.50 | 10.84 | 2.50 | 3.11 |
| ROA %i | -19.55 | 3.21 | -6.66 | 7.62 | 1.75 | 2.17 |
| ROIC %i | -23.70 | 3.54 | -8.24 | 8.63 | 1.78 | 2.31 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -106.32 | 19.54 | -31.03 | 40.43 | 10.49 | 15.42 |
| FCF / sales %i | 13.07 | 13.61 | 13.17 | 14.50 | 13.79 | 13.64 |
| Current ratioi | 5.99 | 5.12 | 5.44 | 5.62 | 3.21 | 3.14 |
| Quick ratioi | 4.12 | 3.36 | 3.61 | 3.87 | 2.17 | 2.14 |
| Debt / assetsi | 14.38 | 13.77 | 14.39 | 13.11 | 14.08 | 13.37 |
| LT debt / equityi | 19.87 | 19.16 | 20.15 | 18.09 | 13.74 | 13.05 |
| Interest coveragei | -55.59 | 10.19 | -16.16 | 21.32 | 5.51 | 8.18 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Clinical Diagnostics is the largest reported line at 61.29% of revenue, across 2 reported segments.
- Life Science follows at 38.71%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Clinical Diagnostics61.29%
Life Science38.71%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.